Piramal Pharma Limited (PPL) released its Annual Report for FY2026, showcasing a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report underscores the company's commitment to improving patient outcomes through science-led innovation and operational excellence.
Financial Performance and Global Reach
During FY2026, Piramal Pharma reported revenue from operations of ₹8,869 crore, supported by a diversified business model with 17 global development and manufacturing facilities and a commercial presence across more than 100 countries. Approximately 66% of the company's revenue was generated from regulated markets, reinforcing its strong global footprint.
Leadership Commentary
Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited, stated, "FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth."
Key Business Highlights
Piramal Pharma Solutions (CDMO)
The CDMO business contributed 55% of the company's revenue and continued to strengthen its position as a leading integrated global CDMO, supporting over 500 global customers across the pharmaceutical and biotechnology ecosystem. During the year, the company made strategic investments, including a commitment of US$90 million for expansion in sterile injectables and payload linker capabilities.
Piramal Critical Care
Piramal Critical Care further strengthened its leadership in the US inhaled anesthesia market, retaining its No. 1 position in the US Sevoflurane market. It completed the acquisition of Kenalog and continued to serve over 6,000 hospitals, surgical centres, and clinics globally.
Piramal Consumer Healthcare
The consumer healthcare business delivered ₹1,274 crore in revenue and continued to strengthen its portfolio of over 25 consumer brands. It launched 31 new products and SKUs during FY2026, while its Power Brands recorded 24% growth, contributing 52% of overall consumer healthcare revenue.
Quality and Compliance
Quality remained a cornerstone of the company's operations. During FY2026, Piramal Pharma successfully completed 38 regulatory inspections, including three USFDA inspections. The company maintained its status of zero Official Action Indicated (OAI) observations across all USFDA inspections, reinforcing the strength of its quality systems and compliance standards.
Sustainability Milestones
The company continued to advance its sustainability agenda, achieving a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with the FY2022 baseline, following the approval of its science-based decarbonisation roadmap.
Workforce and Safety
Piramal Pharma continued to strengthen its people-first culture, with a global workforce of over 7,285 employees, while maintaining its strong commitment to workplace safety by achieving zero fatalities for the fifth consecutive year.
About Piramal Pharma Limited
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (integrated CDMO), Piramal Critical Care (complex hospital generics), and Piramal Consumer Healthcare (wellness products). One of its associate companies, Abbvie Therapeutics India Private Limited, is a market leader in ophthalmology in India. PPL also has a strategic minority investment in Yapan Bio Private Limited, operating in biologics and vaccine segments.
